APLS
Apellis·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 6
Bearish signal 0
Consensus Rating "Buy"
Ample Liquidity
High Gross Profit Margin
Significant Net Income Growth
Revenue Beats Expectation
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About APLS
Apellis Pharmaceuticals, Inc.
A commercial-stage biopharmaceutical company focused on the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade
100 Fifth Avenue
, Waltham
, MA 02451
--
Apellis Pharmaceuticals, Inc., was incorporated under the laws of the State of Delaware on September 25, 2009. The Company is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds for the treatment of diseases with high unmet need by inhibiting the complement system (as a component of the immune system) at the level of central protein C3 in the complement cascade. In February 2023, the U.S. Food and Drug Administration (FDA) approved SYFOVRE, the first drug approved for the treatment of geographic atrophy secondary to age-related macular degeneration (GA).
Earnings Call
Q1/2025
Estimate EPS-0.34
Actual EPS-0.74
Estimate Revenue195.90M
Actual Revenue166.80M
Apellis Pharmaceuticals' Q1 2025: Unraveling Contradictions in Co-Pay Assistance, Market Dynamics, and Sales Guidance
May 07,2025 07:26
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-0.48
Actual EPS-0.33
Estimate Revenue188.65M
Actual Revenue178.49M
Apellis Pharmaceuticals' Q2 2025: Unraveling Contradictions in Sales Dynamics, Market Position, and Competitive Landscape
Jul 31,2025 07:40
Earnings Decrypt
Earnings Decrypt
Q3/2025
Estimate EPS0.94
Actual EPS1.67
Estimate Revenue409.16M
Actual Revenue458.60M
Apellis Pharmaceuticals' Q3 2025 Earnings Call: Contradictions Emerge on Market Growth, Revenue & Market Share, Co-Pay Assistance, EMPAVELI Launch, and SYFOVRE Sales
Oct 30,2025 10:00
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
APLS has released its 2025 Q3 earnings. EPS was reported at 1.67, versus the expected 0.94, beating expectations. The chart below visualizes how APLS has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
APLS has released its 2025 Q3 earnings report, with revenue of 458.58M, reflecting a YoY change of 132.98%, and net profit of 215.72M, showing a YoY change of 475.52%. The Sankey diagram below clearly presents APLS's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
